News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEvents
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Ellen T. Matloff, MS, CGC, President

Advertisement

Articles by Ellen T. Matloff, MS, CGC, President

What to Do When a Patient Brings in Direct-to-Consumer Genetic Test Results for Your Review

ByEllen T. Matloff, MS, CGC, President,CEO, My Gene Counsel
February 4th 2019

A guide for oncology nurses on navigating the ever-growing field of direct-to-consumer genetic testing.

Advertisement

Latest Updated Articles

  • What to Do When a Patient Brings in Direct-to-Consumer Genetic Test Results for Your Review
    What to Do When a Patient Brings in Direct-to-Consumer Genetic Test Results for Your Review

    Published: February 4th 2019 | Updated:



Advertisement
Advertisement

Trending on Oncology Nursing News

1

Pirtobrutinib Wins Traditional FDA Approval in CLL and SLL

2

FDA Approves Liso-Cel in Pretreated R/R Marginal Zone Lymphoma

3

Balancing Benefit and Toxicity in Adjuvant Therapy for Cervical Cancer

4

Rx Road Map: Adagrasib With Cetuximab for KRAS G12C-Mutated mCRC

5

Should I Still Worry About Hazardous Drugs as an Oncology Nurse?

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us